Evidence map›Paper›PMID 34859382›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.

Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro, Assunta Bianco, Mariagrazia Rossi, Alessandra Cicia, Antonio Cortese, Alessandro Cruciani, Valeria De Arcangelis, Laura De Giglio and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Article
  11. Article
  12. Review
  13. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Hypogammaglobulinemia is associated with reduced antibody response after anti-SARS-CoV-2 vaccination in MS patients treated with antiCD20 therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Fioravante CaponeNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy. f.capone@unicampus.it.ORCID 0000-0002-7639-5104
Matteo LucchiniUOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Elisabetta FerraroMultiple Sclerosis Centre, S. Filippo Neri Hospital, Rome, Italy.
Assunta BiancoUOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Mariagrazia RossiNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy.
Alessandra CiciaUOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Antonio CorteseMultiple Sclerosis Centre, S. Filippo Neri Hospital, Rome, Italy.
Alessandro CrucianiNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy.
Valeria De ArcangelisUOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Laura De GiglioMultiple Sclerosis Centre, S. Filippo Neri Hospital, Rome, Italy.
Francesco MotoleseNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy.
Biagio SancettaNeurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy.
Massimiliano Mirabella *UOC Neurologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Vincenzo Di Lazzaro *Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Rome, 00128, Italy.
Università Campus Bio-Medico · ITUniversità Cattolica del Sacro Cuore · ITOspedale San Filippo Neri · ITAgostino Gemelli University Polyclinic · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the immunogenicity and safety of mRNA COVID-19 vaccines in a convenience sample of 140 MS patients treated with different DMTs, undergoing vaccination between April and June 2021. Humoral immune response was tested 1 month after the second dose, using a chemiluminescent microparticle immunoassay to detect IgG against SARS-CoV-2 nucleoprotein. We explored the potential correlation between the IgG titer and DMTs. All patients in treatment with first-line DMTs, natalizumab, cladribine, and alemtuzumab, developed a measurable humoral response. In patients treated with ocrelizumab and fingolimod, the IgG level was significantly lower, but only some patients (22.2% for fingolimod and 66% for ocrelizumab) failed to develop a measurable humoral response. In the ocrelizumab group, the IgG level was positively correlated with the time from last infusion. No SARS-CoV-2 infections were reported after vaccination. The most reported side effects were pain at the injection site (57.1%) and fatigue (37.9%). No patient experienced severe side effects requiring hospitalization. Our study confirms that COVID-19 vaccination is safe and well-tolerated in MS patients and should be recommended to all patients regardless of their current DMTs. Since fingolimod and ocrelizumab could reduce the humoral immune response, in patients treated with these drugs, detecting SARS-CoV-2 antibodies could be helpful to monitor the immune response after vaccination.

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineMultiple SclerosisAntibodies, Monoclonal, HumanizedAntibodies, ViralFingolimod HydrochlorideHumansImmunity, HumoralImmunoglobulin GSARS-CoV-2Antibodies, Monoclonal, HumanizedAntibodies, ViralCOVID-19 VaccinesFingolimod HydrochlorideImmunoglobulin GocrelizumabCOVID-19Disease-modifying therapiesHumoral responseImmunogenicityMultiple sclerosisVaccination

Identifiers

PMID34859382
PMCPMC8639214
OpenAlexW3216933053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.